Company Name | Bayer Taiwan Co., Ltd. |
---|---|
Protocol Number | XA1402 (Impact 17237) |
Title of Study | Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia |
Primary Objective | Following the findings of the clinical trials in drug development, this globalnon-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE). |
Number of Sites | Expected to have 8 |
Period of Study | From:2014-11-1 to:2016-10-31 |
Number of Patients | 200人 |
IRB Approval Date | Currently under review |
Publication Plan / Date | TBD |